FATE THERAPEUTICS INC (FATE) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $3.00K; Common Stock, Value, IssuedUSD $117.00K; Additional Paid in CapitalUSD $1.75B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-117.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $3.00K; Common Stock, Value, IssuedUSD $116.00K; Additional Paid in CapitalUSD $1.75B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-77.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $3.00K; Common Stock, Value, IssuedUSD $115.00K; Additional Paid in CapitalUSD $1.74B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $116.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $3.00K; Common Stock, Value, IssuedUSD $115.00K; Additional Paid in CapitalUSD $1.74B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $153.00K.
FATE THERAPEUTICS INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.00K | $117.00K | $1.75B | $-117.00K | $-1.60B | $153.44M | (m) | 3 month · $3.52M | (m) | (m) |
| 2026-03-31 | $3.00K | $116.00K | $1.75B | $-77.00K | $-1.57B | $179.71M | (m) | 3 month · $3.93M | (m) | (m) |
| 2025-12-31 | $3.00K | $115.00K | $1.74B | $116.00K | $-1.53B | $207.18M | (m) | 12 month · $24.92M | (m) | (m) |
| 2025-09-30 | $3.00K | $115.00K | $1.74B | $153.00K | $-1.50B | $234.07M | (m) | 3 month · $4.86M | (m) | (m) |
| 2025-06-30 | $3.00K | $115.00K | $1.73B | $62.00K | $-1.47B | $261.36M | (m) | 3 month · $7.15M | (m) | (m) |
| 2025-03-31 | $3.00K | $115.00K | $1.72B | $191.00K | $-1.44B | $288.41M | 3 month · $0.00 | 3 month · $7.38M | (m) | (m) |
| 2024-12-31 | $3.00K | $114.00K | $1.72B | $268.00K | $-1.40B | $318.73M | (m) | 12 month · $41.50M | (m) | (m) |
| 2024-09-30 | $3.00K | $114.00K | $1.71B | $835.00K | $-1.35B | $362.33M | (m) | 3 month · $11.77M | (m) | (m) |
| 2024-06-30 | $3.00K | $114.00K | $1.70B | $-422.00K | $-1.30B | $396.98M | 6 month · $0.00 | 3 month · $9.63M | (m) | (m) |
| 2024-03-31 | $3.00K | $114.00K | $1.69B | $-194.00K | $-1.26B | $426.12M | 3 month · $558.00K | 3 month · $10.98M | (m) | (m) |
| 2023-12-31 | $3.00K | $99.00K | $1.58B | $15.00K | $-1.21B | $368.42M | (m) | 12 month · $43.46M | (m) | (m) |
| 2023-09-30 | $3.00K | $99.00K | $1.57B | $-499.00K | $-1.17B | $402.78M | (m) | 3 month · $10.10M | (m) | (m) |
| 2023-06-30 | $3.00K | $99.00K | $1.56B | $-587.00K | $-1.12B | $437.75M | 6 month · $62.00K | 3 month · $12.90M | (m) | (m) |
| 2023-03-31 | $3.00K | $98.00K | $1.55B | $-646.00K | $-1.07B | $477.47M | 3 month · $0.00 | 3 month · $10.98M | (m) | (m) |
| 2022-12-31 | $3.00K | $97.00K | $1.54B | $-1.85M | $-1.05B | $483.94M | 12 month · $0.00 | 12 month · $78.73M | (m) | (m) |
| 2022-09-30 | $3.00K | $97.00K | $1.52B | $-3.25M | $-994.44M | $518.00M | (m) | 3 month · $19.47M | (m) | (m) |
| 2022-06-30 | $3.00K | $97.00K | $1.49B | $-3.38M | $-910.88M | $580.48M | (m) | 3 month · $20.54M | (m) | (m) |
| 2022-03-31 | $3.00K | $97.00K | $1.47B | $-2.85M | $-834.77M | $633.39M | (m) | 3 month · $19.33M | (m) | (m) |
| 2021-12-31 | $3.00K | $96.00K | $1.45B | $-762.00K | $-769.08M | $678.84M | 12 month · $133.00K | 12 month · $54.36M | (m) | (m) |
| 2021-09-30 | $3.00K | $95.00K | $1.43B | $-73.00K | $-700.46M | $730.33M | (m) | 3 month · $13.54M | (m) | (m) |
| 2021-06-30 | $3.00K | $94.00K | $1.41B | $-86.00K | $-657.15M | $752.07M | (m) | 3 month · $13.25M | (m) | (m) |
| 2021-03-31 | $3.00K | $94.00K | $1.39B | $-260.00K | $-602.02M | $790.10M | (m) | 3 month · $12.98M | (m) | (m) |
| 2020-12-31 | $3.00K | $88.00K | $941.22M | $70.00K | $-556.93M | $384.44M | 12 month · $0.00 | 12 month · $30.75M | (m) | (m) |
| 2020-09-30 | $3.00K | $87.00K | $927.78M | $312.00K | $-503.82M | $424.37M | (m) | 3 month · $7.84M | (m) | (m) |
| 2020-06-30 | $3.00K | $87.00K | $918.53M | $623.00K | $-445.14M | $474.11M | (m) | 3 month · $7.24M | (m) | (m) |
| 2020-03-31 | $3.00K | $76.00K | $636.06M | $142.00K | $-417.06M | $219.22M | (m) | 3 month · $6.91M | (m) | (m) |
| 2019-12-31 | $3.00K | $76.00K | $628.20M | $22.00K | $-383.55M | $244.76M | (m) | 12 month · $17.41M | (m) | (m) |
| 2019-09-30 | $3.00K | $75.00K | $623.16M | $51.00K | $-355.24M | $268.04M | (m) | 3 month · $4.57M | (m) | (m) |
| 2019-06-30 | $3.00K | $65.00K | $456.00M | $93.00K | $-328.63M | $127.53M | (m) | 3 month · $4.39M | (m) | (m) |
| 2019-03-31 | $3.00K | $65.00K | $450.93M | (m) | $-305.16M | $145.84M | (m) | 3 month · $3.87M | (m) | (m) |
| 2018-12-31 | $3.00K | $65.00K | $445.80M | $-2.00K | $-285.40M | $160.47M | (m) | 12 month · $6.29M | (m) | (m) |
| 2018-09-30 | $3.00K | $65.00K | $443.24M | $-14.00K | $-269.37M | $173.93M | (m) | 3 month · $1.64M | (m) | (m) |
| 2018-06-30 | $3.00K | $53.00K | $304.37M | $-15.00K | $-252.59M | $51.83M | 3 month · $19.00K | 3 month · $1.49M | (m) | (m) |
| 2018-03-31 | $3.00K | $53.00K | $297.88M | $-13.00K | $-232.93M | $65.00M | 3 month · $37.00K | 3 month · $1.38M | (m) | (m) |
| 2017-12-31 | $3.00K | $53.00K | $295.93M | $-3.00K | $-218.80M | $77.19M | (m) | 12 month · $3.61M | (m) | 12 month · $217.00K |
| 2017-09-30 | $3.00K | $41.00K | $252.02M | $-13.00K | $-206.30M | $45.75M | 3 month · $13.00K | 3 month · $871.00K | (m) | 3 month · $217.00K |
| 2017-06-30 | $3.00K | $41.00K | $250.82M | $-39.00K | $-195.62M | $55.21M | (m) | 3 month · $973.00K | (m) | (m) |
| 2017-03-31 | $3.00K | $41.00K | $249.82M | $-34.00K | $-185.97M | $63.86M | (m) | 3 month · $867.00K | (m) | (m) |
| 2016-12-31 | $3.00K | $41.00K | $248.96M | $-1.00K | $-175.85M | $73.15M | (m) | 12 month · $3.18M | $248.96M | (m) |
| 2016-09-30 | (m) | $34.00K | (m) | $3.00K | $-167.91M | $25.37M | (m) | (m) | $193.24M | (m) |
| 2016-06-30 | (m) | $29.00K | (m) | $11.00K | $-159.17M | $23.13M | (m) | (m) | $182.26M | (m) |
| 2016-03-31 | (m) | $29.00K | (m) | $14.00K | $-150.76M | $30.73M | (m) | (m) | $181.44M | (m) |
| 2015-12-31 | (m) | $29.00K | (m) | (m) | $-142.38M | $38.04M | (m) | 12 month · $2.40M | $180.39M | (m) |
| 2015-09-30 | (m) | $29.00K | $179.90M | (m) | $-134.94M | $44.99M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $29.00K | $179.10M | (m) | $-128.05M | $51.07M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $21.00K | $141.50M | (m) | $-120.27M | $21.25M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $21.00K | $140.71M | (m) | $-112.39M | $28.34M | (m) | 12 month · $2.43M | $140.71M | 12 month · $375.00K |
| 2014-09-30 | (m) | $21.00K | $139.71M | (m) | $-106.16M | $33.58M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $21.00K | $139.17M | (m) | $-99.56M | $39.64M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $20.00K | $138.65M | (m) | (m) | $45.18M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $20.00K | $137.34M | (m) | $-86.51M | $50.85M | (m) | 12 month · $1.55M | (m) | 12 month · $192.00K |
| 2013-09-30 | (m) | $1.00K | $14.37M | (m) | (m) | $-66.40M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.00K | $12.79M | (m) | (m) | $-52.83M | (m) | 12 month · $155.00K | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | $-50.68M | (m) | 12 month · $172.00K | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | $-37.44M | (m) | 12 month · $229.00K | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $-21.46M | (m) | 12 month · $196.00K | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $-8.35M | (m) | 12 month · $17.00K | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | $-1.22M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |